570 related articles for article (PubMed ID: 22974666)
1. Prescriptions for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and monitoring of serum creatinine and potassium in patients with chronic kidney disease.
Wang PT; Huang YB; Lin MY; Chuang PF; Hwang SJ
Kaohsiung J Med Sci; 2012 Sep; 28(9):477-83. PubMed ID: 22974666
[TBL] [Abstract][Full Text] [Related]
2. Laboratory monitoring of potassium and creatinine in ambulatory patients receiving angiotensin converting enzyme inhibitors and angiotensin receptor blockers.
Raebel MA; McClure DL; Simon SR; Chan KA; Feldstein A; Andrade SE; Lafata JE; Roblin D; Davis RL; Gunter MJ; Platt R
Pharmacoepidemiol Drug Saf; 2007 Jan; 16(1):55-64. PubMed ID: 16470693
[TBL] [Abstract][Full Text] [Related]
3. Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia.
Hsu TW; Liu JS; Hung SC; Kuo KL; Chang YK; Chen YC; Hsu CC; Tarng DC
JAMA Intern Med; 2014 Mar; 174(3):347-54. PubMed ID: 24343093
[TBL] [Abstract][Full Text] [Related]
4. Effects of the Renin-Angiotensin system blockade on hemoglobin levels in type 2 diabetic patients with chronic kidney disease.
Inoue A; Babazono T; Iwamoto Y
Am J Hypertens; 2008 Mar; 21(3):317-22. PubMed ID: 18202667
[TBL] [Abstract][Full Text] [Related]
5. Is Chronic Kidney Disease Progression Influenced by the Type of Renin-Angiotensin-System Blocker Used?
Silvariño R; Rios P; Baldovinos G; Chichet MA; Perg N; Sola L; Saona G; De Souza N; Lamadrid V; Gadola L
Nephron; 2019; 143(2):100-107. PubMed ID: 31203280
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease.
Sharma P; Blackburn RC; Parke CL; McCullough K; Marks A; Black C
Cochrane Database Syst Rev; 2011 Oct; (10):CD007751. PubMed ID: 21975774
[TBL] [Abstract][Full Text] [Related]
7. Proteinuria as a risk marker for the progression of chronic kidney disease in patients on predialysis care and the role of angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker treatment.
de Goeij MC; Liem M; de Jager DJ; Voormolen N; Sijpkens YW; Rotmans JI; Boeschoten EW; Dekker FW; Grootendorst DC; Halbesma N;
Nephron Clin Pract; 2012; 121(1-2):c73-82. PubMed ID: 23128440
[TBL] [Abstract][Full Text] [Related]
8. Facility variation in utilization of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with diabetes mellitus and chronic kidney disease.
Tiwari A; Tseng CL; Kern EF; Maney M; Miller DR; Pogach L
Am J Manag Care; 2007 Feb; 13(2):73-9. PubMed ID: 17286527
[TBL] [Abstract][Full Text] [Related]
9. No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients.
Han SW; Won YW; Yi JH; Kim HJ
Nephrol Dial Transplant; 2007 Apr; 22(4):1150-5. PubMed ID: 17255126
[TBL] [Abstract][Full Text] [Related]
10. Effects of adding Rheum officinale to angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on renal function in patients with chronic renal failure: A meta-analysis of randomized controlled trials
.
Yang Y; Ma YP; Zhang Z; Dai PL; Li P; Li WG
Clin Nephrol; 2018 Jun; 89(6):445-454. PubMed ID: 29208203
[TBL] [Abstract][Full Text] [Related]
11. A comparison between angiotensin converting enzyme inhibitors and angiotensin receptor blockers on end stage renal disease and major adverse cardiovascular events in diabetic patients: a population-based dynamic cohort study in Taiwan.
Wu LS; Chang SH; Chang GJ; Liu JR; Chan YH; Lee HF; Wen MS; Chen WJ; Yeh YH; Kuo CT; See LC
Cardiovasc Diabetol; 2016 Apr; 15():56. PubMed ID: 27039185
[TBL] [Abstract][Full Text] [Related]
12. Long-term changes of renal function in relation to ace inhibitor/angiotensin receptor blocker dosing in patients with heart failure and chronic kidney disease.
Fröhlich H; Nelges C; Täger T; Schwenger V; Cebola R; Schnorbach J; Goode KM; Kazmi S; Katus HA; Cleland JG; Clark AL; Frankenstein L
Am Heart J; 2016 Aug; 178():28-36. PubMed ID: 27502849
[TBL] [Abstract][Full Text] [Related]
13. Higher serum potassium level associated with late stage chronic kidney disease.
Hsieh MF; Wu IW; Lee CC; Wang SY; Wu MS
Chang Gung Med J; 2011; 34(4):418-25. PubMed ID: 21880197
[TBL] [Abstract][Full Text] [Related]
14. [Can angiotensin-converting enzyme inhibitor be used in chronic kidney disease patients with serum creatinine level greater than 266 micromol/L?].
Zhang GH; Hou FF; Zhang X; Liu QF
Zhonghua Nei Ke Za Zhi; 2005 Aug; 44(8):592-6. PubMed ID: 16194413
[TBL] [Abstract][Full Text] [Related]
15. EVALUATING THE PRESCRIPTION OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS OR RECEPTOR BLOCKERS IN PATIENTS WITH DIABETES IN JORDAN.
Mayyas F; Bataineh W; Jarab A
Endocr Pract; 2017 Nov; 23(11):1289-1296. PubMed ID: 28816537
[TBL] [Abstract][Full Text] [Related]
16. Pentoxifylline plus ACEIs/ARBs for proteinuria and kidney function in chronic kidney disease: a meta-analysis.
Liu D; Wang LN; Li HX; Huang P; Qu LB; Chen FY
J Int Med Res; 2017 Apr; 45(2):383-398. PubMed ID: 28415944
[TBL] [Abstract][Full Text] [Related]
17. Effects of spironolactone in combination with angiotensin-converting enzyme inhibitors or Angiotensin receptor blockers in patients with proteinuria.
Kim HY; Bae EH; Ma SK; Kim SW
Kidney Blood Press Res; 2014; 39(6):573-80. PubMed ID: 25531940
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of chronic kidney disease and its risk factors among family practice patients in Lithuania.
Bumblyte IA; Zilinskiene A; Vanholder R; Valius L; Kuzminskis V
Clin Nephrol; 2012 Sep; 78(3):198-206. PubMed ID: 22874108
[TBL] [Abstract][Full Text] [Related]
19. Serum potassium in stage 5 CKD patients on their first presentation in a dialysis service of a county hospital in western Romania.
Gluhovschi G; Mateş A; Gluhovschi C; Golea O; Gădălean F; Somai M; Ene I; Petrica L; Velciov S
Rom J Intern Med; 2014; 52(1):30-8. PubMed ID: 25000676
[TBL] [Abstract][Full Text] [Related]
20. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis.
Cheng J; Zhang W; Zhang X; Han F; Li X; He X; Li Q; Chen J
JAMA Intern Med; 2014 May; 174(5):773-85. PubMed ID: 24687000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]